CHEST pulmonary最新文献

{"title":"Quantifying Normal Diaphragmatic Motion and Shape and Their Developmental Changes via Dynamic MRI","authors":"You Hao PhD ,&nbsp;Jayaram K. Udupa PhD ,&nbsp;Yubing Tong PhD ,&nbsp;Caiyun Wu PhD ,&nbsp;Joseph M. McDonough MS ,&nbsp;Samantha Gogel BA ,&nbsp;Oscar H. Mayer MD ,&nbsp;Mostafa Alnoury MD ,&nbsp;Patrick J. Cahill MD ,&nbsp;Jason B. Anari MD ,&nbsp;Drew A. Torigian MD","doi":"10.1016/j.chpulm.2024.100115","DOIUrl":"10.1016/j.chpulm.2024.100115","url":null,"abstract":"<div><h3>Background</h3><div>The diaphragm is a critical structure in respiratory function; however, in vivo quantitative description of its motion available in the literature is limited.</div></div><div><h3>Research Question</h3><div>How do we quantitatively describe regional hemidiaphragmatic motion and curvature via free-breathing dynamic MRI (dMRI)?</div></div><div><h3>Study Design and Methods</h3><div>In this prospective cohort study, we gathered dMRI images of 177 healthy children and young adults and segmented hemidiaphragm domes in end-inspiration and end-expiration phases of the constructed 4-dimensional image. We selected 25 points uniformly located on each 3-dimensional (3D) hemidiaphragm surface. Based on the motion and local shape of hemidiaphragm at these points, we computed the velocities and sagittal and coronal curvatures in 13 regions on each hemidiaphragm surface and analyzed the change in these properties with age and sex.</div></div><div><h3>Results</h3><div>This cohort consisted of 94 female patients (range, 6-20 years; mean ± SD, 12.09 ± 3.73 years) and 83 male patients (range, 6-20 years; mean ± SD, 11.88 ± 3.57 years). We observed the following: velocity range: approximately 2 to approximately 13 mm/s; and curvature range: sagittal: approximately 3 to approximately 27 m⁻¹ and coronal: ∼approximately 6 to approximately 20 m⁻¹. There was no significant difference in velocity between sexes; however, the pattern of change in velocity with age was different for the 2 groups. Strong correlations in velocity were observed between homologous regions of right and left hemidiaphragms. There was no significant difference in curvatures between sexes or change in curvatures with age.</div></div><div><h3>Interpretation</h3><div>Regional motion/curvature of the 3D diaphragmatic surface can be estimated using free-breathing dMRI. Our analysis sheds light on heretofore unknown matters such as how the pediatric 3D hemidiaphragm motion/shape varies regionally, between right and left hemidiaphragms, between sexes, and with age.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"3 1","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Dramatic Decline in Lung Transplantation for Cystic Fibrosis in the United States","authors":"Tijana Milinic MD ,&nbsp;Kathleen J. Ramos MD, MSc ,&nbsp;Eliana R. Gill PhD ,&nbsp;Nora Burdis MD ,&nbsp;Christopher H. Goss MD, MSc ,&nbsp;Siddhartha G. Kapnadak MD","doi":"10.1016/j.chpulm.2024.100077","DOIUrl":"10.1016/j.chpulm.2024.100077","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Rapid On-Site Cytology Evaluation Cost-Effective in Navigational Bronchoscopy? The Challenge of Modeling Benefit in the Rapidly Evolving Landscape of Advanced Diagnostic Bronchoscopy","authors":"Kim Styrvoky MD ,&nbsp;Dominique J. Pepper MD","doi":"10.1016/j.chpulm.2024.100078","DOIUrl":"10.1016/j.chpulm.2024.100078","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 53-Year-Old Woman With Stage IV Non-Small Cell Lung Cancer and Progressive Paratracheal Lymphadenopathy","authors":"Alberto Goizueta MD ,&nbsp;Aileen Anglin APRN, ACNP-BC, AOCNP ,&nbsp;Bruce F. Sabath MD","doi":"10.1016/j.chpulm.2024.100081","DOIUrl":"10.1016/j.chpulm.2024.100081","url":null,"abstract":"<div><h3>Case Presentation</h3><div>A 53-year-old woman with a history of <em>EGFR</em> mutation-positive stage IV lung adenocarcinoma underwent scheduled surveillance imaging. The disease was stable with osimertinib treatment for the preceding 24 months. Surveillance imaging noted new paratracheal adenopathy concerning for cancer progression. She was referred to interventional pulmonology for bronchoscopic evaluation. She provided written informed consent.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141716748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancytopenia and Progressive Breathlessness in a 48-Year-Old Man With a Reversed Halo Sign on Imaging","authors":"Rakesh Kodati MD, DM ,&nbsp;Narendra Kumar Narahari MD ,&nbsp;Shantveer G. Uppin MD ,&nbsp;Umabala Pamidimukkala MD ,&nbsp;Sukanya Sudhaharan MD ,&nbsp;Bhaskar Kakarla MD ,&nbsp;Paramjyothi Gongati MD","doi":"10.1016/j.chpulm.2024.100088","DOIUrl":"10.1016/j.chpulm.2024.100088","url":null,"abstract":"<div><h3>Case Presentation</h3><div>A 48-year-old man with no prior medical comorbidities was admitted to our pulmonology department with progressive breathlessness, dry cough, and low-grade fever of 2 months’ duration. Breathlessness was of insidious onset and progressed gradually from level 1 to level 4 on the modified Medical Research Council scale over 2 months. He did not report any orthopnoea or paroxysmal nocturnal dyspnea. The cough did not have any allergic triggers and had no diurnal variation. He had on-and-off low-grade fever with no specific pattern. He had no history of smoking and had no other substance dependencies. He was evaluated initially at a primary care centre with a chest CT scan, which showed patchy distribution of ground-glass opacities (GGOs) with no lobar predilection and random nodules in the left upper lobe. It also showed round lesions in the right upper lobe with central GGOs surrounded by a rim of consolidation suggestive of reversed halo sign (RHS). Routine blood investigation findings (complete blood count and kidney and liver functions tests) were normal. He was advised to undergo a lung biopsy for definite diagnosis, but he declined to do so. A provisional diagnosis of organizing pneumonia was made based on the CT scan findings of RHS and oral glucocorticoids administration was started. No clinical improvement was seen after 1 month of steroid therapy, and he was referred to us.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100088"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Clinical Practices in Follow-Up of Nonmalignant Pulmonary Nodules After Bronchoscopic Biopsy","authors":"Camilo A. Avendano ,&nbsp;Luis O. Gerena-Montano ,&nbsp;Jason A. Beattie ,&nbsp;Mihir S. Parikh ,&nbsp;Kai E. Swenson ,&nbsp;Adnan Majid ,&nbsp;Chenchen Zhang MD, PhD","doi":"10.1016/j.chpulm.2024.100112","DOIUrl":"10.1016/j.chpulm.2024.100112","url":null,"abstract":"<div><h3>Background</h3><div>Management of nonmalignant nodules after bronchoscopic biopsy lacks thorough investigation, leading to varied clinical approaches.</div></div><div><h3>Research Question</h3><div>What are the true-negative and false-negative rates of nonmalignant nodules by bronchoscopic biopsy, and what is the clinical practice pattern for follow-up?</div></div><div><h3>Study Design and Methods</h3><div>A retrospective review was conducted for pulmonary nodules biopsied via bronchoscopy between 2019 and 2020 revealing no malignancy. True-negative and false-negative rates were calculated. Clinical practice patterns for repeat biopsy and follow-up imaging studies were analyzed using time-to-event analysis. Covariates, including sex, age, smoking history, nodule size, maximum standardized uptake values, active cancer diagnosis, bronchoscopy type, and nodule pathologic findings, were evaluated for their impact on clinical decision-making.</div></div><div><h3>Results</h3><div>Among 136 patients with 139 nodules analyzed, only 39.6% of nodules were classified definitively as benign (true-negative rate), whereas 23.7% of nodules were deemed malignant (false-negative rate). Repeat biopsy was performed for 35.3% of nodules, and 66.9% of patients underwent follow-up CT imaging. Nodules initially diagnosed with suspicious or atypical pathologic results reached a final diagnosis (hazard ratio, 3.65; 95% CI, 1.33-9.99) earlier than those with nondiagnostic pathologic findings. Patients with such nodules underwent repeat biopsy sooner (χ² = 15.85; <em>P</em> = .000) and exhibited a trend toward earlier repeat CT scans (χ² = 5.93; <em>P</em> = .052).</div></div><div><h3>Interpretation</h3><div>After bronchoscopic biopsy, a 2-year follow-up revealed a notable lack of high true-negative rates for nonmalignant nodules, alongside significant false-negative rates. Diverse clinical practices, including repeat biopsy and follow-up CT scans, were observed in managing nonmalignant nodules.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Volume Changes in Stable Preterm Infants Weaned From Nasal CPAP to High Flow","authors":"Vanessa L. Büchler MD ,&nbsp;Vincent D. Gaertner MD ,&nbsp;Janine Thomann MD ,&nbsp;Dirk Bassler MD ,&nbsp;Christoph M. Rüegger MD","doi":"10.1016/j.chpulm.2024.100094","DOIUrl":"10.1016/j.chpulm.2024.100094","url":null,"abstract":"<div><h3>Background</h3><div>Weaning preterm infants off nasal CPAP (nCPAP) using nasal high-flow therapy has gained popularity. The effects of such a weaning strategy on lung volumes are unclear.</div></div><div><h3>Research Question</h3><div>How does the transition from nCPAP to high flow and varying flow levels affect lung volumes in stable preterm infants?</div></div><div><h3>Study Design and Methods</h3><div>This was a prospective cohort study in infants 30 to 35 weeks’ postmenstrual age. After a baseline period on nCPAP 5 cm H₂O, infants were switched to high flow 8 L/min for 30 minutes. The flow level was reduced by 2 L/min every 30 minutes to a minimum of 2 L/min and subsequently increased to the initial level of 8 L/min, followed by another nCPAP period. Using electrical impedance tomography, end-expiratory lung impedance as a proxy for end-expiratory lung volume (EELV) and cardiorespiratory parameters were recorded at each flow level and compared with baseline.</div></div><div><h3>Results</h3><div>Overall, 8,438 breaths from 19 infants were analyzed. EELV changed significantly during the study (<em>P</em> = .002), which was mainly attributable to a loss of EELV when high flow was reduced to 6 and 4 L/min and re-escalated to 4, 6, and 8 L/min. Apart from a reduction in minute ventilation (<em>P</em> = .004), no other significant changes were found in electrical impedance tomography ventilation parameters. Alterations in lung volume were accompanied by an increase in heart rate (<em>P</em> = .02) and a decrease in peripheral oxygen saturation/F<span>io</span>₂ ratio (<em>P</em> &lt; .001).</div></div><div><h3>Interpretation</h3><div>The results of this study indicate that the transition from nCPAP to high flow is likely to result in a reduced EELV, accompanied by physiological responses in heart rate and oxygenation. Despite a stepwise escalation to preweaning flow levels, we found that only partial recovery of lung volume losses was achievable with high flow.</div></div><div><h3>Clinical Trial Registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>; No.: <span><span>NCT05237622</span><svg><path></path></svg></span>; URL: <span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span></div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions to Improve Quality of Life and Knowledge in Hypersensitivity Pneumonitis","authors":"Kerri I. Aronson MD ,&nbsp;Nancy Holbrook MD ,&nbsp;Armani Edgar BS ,&nbsp;Michaela R. Anderson MD ,&nbsp;Jamuna K. Krishnan MD ,&nbsp;Robert J. Kaner MD ,&nbsp;Anna J. Podolanczuk MD ,&nbsp;Fernando J. Martinez MD ,&nbsp;Jonathan N. Tobin PhD ,&nbsp;Monika M. Safford MD","doi":"10.1016/j.chpulm.2024.100083","DOIUrl":"10.1016/j.chpulm.2024.100083","url":null,"abstract":"<div><h3>Background</h3><div>Behavioral and educational interventions are promising approaches to improve health-related quality of life (HRQOL); however, few have been studied in hypersensitivity pneumonitis (HP) or other interstitial lung diseases (ILDs). The objective of this study was to gather ILD clinicians’ current practices and perspectives on the management of HRQOL and disease-specific education in HP, level of knowledge about, and attitudes toward behavioral and educational interventions and to identify potential clinician-perceived barriers to address during intervention development.</div></div><div><h3>Study Question</h3><div>What are the current practices and perspectives of ILD clinicians regarding the management of HRQOL and disease-specific education, and what is their level of knowledge about and attitude toward a potential virtual behavioral and educational intervention to address HRQOL in HP?</div></div><div><h3>Study Design and Methods</h3><div>An electronic survey was administered to ILD clinicians across the United States. Survey data were analyzed using descriptive statistics, and open-ended questions were analyzed using qualitative content analysis.</div></div><div><h3>Results</h3><div>Seventy-four clinicians responded to the survey, of whom 93% identified as physicians. All respondents (100%) indicated that offering an intervention to improve HRQOL in their patients with HP is either very important or absolutely essential. Only 5% of clinicians reported currently using a validated assessment tool to measure HRQOL. When asked about specific behavioral intervention techniques, most clinicians (92%) reported possessing a small amount of or zero knowledge about peer coaching interventions and a small amount of or zero knowledge (69%) about cognitive behavioral therapy principles. Despite this, most clinicians (68%) desire the ability to educate their patients about these potentially effective behavioral interventions, and most clinicians (67%) indicated the desire to reinforce the principles of an intervention after completion. Perceived barriers to referring patients to a virtually delivered behavioral intervention included time constraints, availability and access for all patients, cost and reimbursement, and difficulty with technology.</div></div><div><h3>Interpretation</h3><div>Clinicians in this survey unanimously agree that interventions to improve HRQOL and knowledge are needed for people living with HP. Clinicians’ desire for involvement in education, referral, and reinforcement of these interventions will require clinician education in behavioral strategies and implementation-related strategies early in the development process.</div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100083"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient Registry","authors":"Mohleen Kang MD, MS ,&nbsp;Sachin Gupta MD ,&nbsp;Yi-Hsuan Tu PhD ,&nbsp;Karina Raimundo MS ,&nbsp;Anisha M. Patel PhD ,&nbsp;Kevin R. Flaherty MD","doi":"10.1016/j.chpulm.2024.100082","DOIUrl":"10.1016/j.chpulm.2024.100082","url":null,"abstract":"<div><h3>Background</h3><div>Patients with idiopathic pulmonary fibrosis (IPF) experience debilitating symptoms. Although antifibrotics may slow lung function decline, their impact on patients’ health-related quality of life and disease symptoms in the real world remains unknown.</div></div><div><h3>Research Question</h3><div>What is the impact of pirfenidone vs no treatment on health-related quality of life and IPF-related symptoms of cough, dyspnea, and fatigue?</div></div><div><h3>Study Design and Methods</h3><div>This retrospective analysis included patients with IPF aged ≥ 55 years enrolled in the Pulmonary Fibrosis Foundation Patient Registry between March 2016 and December 2021. Change from baseline in patient-reported outcome measures (PROMs), including the Leicester Cough Questionnaire, University of California, San Diego Shortness of Breath Questionnaire (UCSD SOBQ), Fatigue Severity Scale, and Short-Form 6-Dimension questionnaire were assessed at months 6, 12, and 18 in patients receiving pirfenidone vs no treatment. A marginal structure model accounted for time-varying confounding caused by FVC % predicted and diffusing capacity of the lungs for carbon monoxide % predicted.</div></div><div><h3>Results</h3><div>In the Leicester Cough Questionnaire population (n = 237; pirfenidone, n = 155; no treatment, n = 82), treatment groups differed in age, insurance, and FVC % predicted. In the unadjusted analyses, mean changes in PROMs differed numerically between treatment groups; however, based on the marginal structure model, no significant differences were found in adjusted mean changes in PROMs. When analyzed by Gender, Age, and Physiology score, a clinically meaningful reduction in worsening of pirfenidone vs no treatment was observed in the adjusted mean change of UCSD SOBQ score at month 12 in patients with Gender, Age, and Physiology score stage 2/3.</div></div><div><h3>Interpretation</h3><div>Similar to previous findings, the difference in UCSD SOBQ scores observed in this real-world analysis suggests that patients with more advanced IPF may experience less dyspnea when receiving pirfenidone vs no treatment. Further research is needed to confirm this finding.</div></div><div><h3>Trial Registry</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>; No.: NCT02758808; URL: <span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span></div></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100082"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141704494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chest Wall Deformities in Adults With Fibrotic Interstitial Lung Disease Related to Surfactant-Related Gene Mutations","authors":"Margot Delin MD ,&nbsp;Marie Pierre Debray MD ,&nbsp;Marie Legendre MD, PhD ,&nbsp;Lidwine Wemeau MD ,&nbsp;Bruno Crestani MD, PhD ,&nbsp;Emmanuel Brian MD ,&nbsp;Justine Frija-Masson MD, PhD ,&nbsp;Laurent Plantier MD, PhD ,&nbsp;Spyros A. Papiris MD ,&nbsp;Effrosyni D. Manali MD ,&nbsp;Nadia Nathan MD, PhD ,&nbsp;Raphael Borie MD, PhD","doi":"10.1016/j.chpulm.2024.100106","DOIUrl":"10.1016/j.chpulm.2024.100106","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 4","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}